Implementation of sorafenib treatment for advanced hepatocellular carcinoma: an illustration of current practice in Taiwan

References

• StravitzRTHeumanDMChandNSurveillance for hepatocellular carcinoma in patients with cirrhosis improves outcomeAm J Med2008121211912618261500
   PubMed Web of Science ®Google Scholar
• LlovetJMBruixJSystematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survivalHepatology200337242944212540794
   PubMed Web of Science ®Google Scholar
• LopezPMVillanuevaALlovetJMSystematic review: evidence-based management of hepatocellular carcinoma – an updated analysis of randomized controlled trialsAliment Pharmacol Ther200623111535154716696801
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
   PubMed Web of Science ®Google Scholar
• ChangYSAdnaneJTrailPASorafenib (Bay 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft modelsCancer Chemother Pharmacol200759556157417160391
   PubMed Web of Science ®Google Scholar
• WilhelmSCarterCLynchMDiscovery and development of sorafenib: a multikinase inhibitor for treating cancerNat Rev Drug Discov200651083584417016424
   PubMed Web of Science ®Google Scholar
• AvilaMABerasainCSangroBPrietoJNew therapies for hepatocellular carcinomaOncogene200625273866388416799628
   PubMed Web of Science ®Google Scholar
• CarlomagnoFAnagantiSGuidaTBay 43-9006 inhibition of oncogenic RET mutantsJ Natl Cancer Inst200698532633416507829
   PubMed Web of Science ®Google Scholar
• HwangYHChoiJYKimSOver-expression of C-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinomaHepatol Res200429211312115163433
   PubMed Web of Science ®Google Scholar
• ChengALKangYKChenZEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialLancet Oncol2009101253419095497
   PubMed Web of Science ®Google Scholar
• FornerAReigMERodriguez de LopeCBruixJCurrent strategy for staging and treatment: the BCLC update and future prospectsSemin Liver Dis2010301617420175034
   PubMed Web of Science ®Google Scholar
• OmataMChengALKokudoNAsia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 updateHepatol Int201711431737028620797
   PubMed Web of Science ®Google Scholar
• OmataMLesmanaLATateishiRAsian Pacific association for the study of the liver consensus recommendations on hepatocellular carcinomaHepatol Int20104243947420827404
   PubMed Web of Science ®Google Scholar
• BruixJShermanMAmerican Association for the study of liver D. management of hepatocellular carcinoma: an updateHepatology20115331020102221374666
   PubMed Web of Science ®Google Scholar
• LuLCChenPJYehYCPrescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: a national population studyAnticancer Res20173752593259928476832
   PubMed Web of Science ®Google Scholar
• NakanoMTanakaMKuromatsuREfficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinomaOncology201384210811423147476
   PubMed Web of Science ®Google Scholar
• ShinginaAHashimAMHaqueMIn a ‘real-world’, clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survivalCan J Gastroenterol201327739339623862169
   PubMed Web of Science ®Google Scholar
• ChanKMYuMCChouHSWuTJLeeCFLeeWCSignificance of tumor necrosis for outcome of patients with hepatocellular carcinoma receiving locoregional therapy prior to liver transplantationAnn Surg Oncol20111892638264621584831
   PubMed Web of Science ®Google Scholar
• AgopianVGHarlander-LockeMPRuizRMImpact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within Milan criteria undergoing liver transplantation: analysis of 3601 patients from the US multicenter HCC transplant ConsortiumAnn Surg2017266352553528654545
   PubMed Web of Science ®Google Scholar
• ChenMYWangYCWuTHEfficacy of external beam radiation-based treatment plus locoregional therapy for hepatocellular carcinoma associated with portal vein tumor thrombosisBioMed Res Int20162016419
   Google Scholar
• KudoMImanakaKChidaNPhase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinomaEur J Cancer201147142117212721664811
   PubMed Web of Science ®Google Scholar
• LencioniRLlovetJMHanGSorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the space trialJ Hepatol20166451090109826809111
   PubMed Web of Science ®Google Scholar
• MeyerTFoxRMaYTSorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trialLancet Gastroenterol Hepatol20172856557528648803
   PubMed Web of Science ®Google Scholar
• CaiRSongRPangPTranscatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysisBMC Cancer201717171429110700
   PubMedGoogle Scholar
• ChungYHHanGYoonJHInterim analysis of start: study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trialInt J Cancer2013132102448245823129123
   PubMed Web of Science ®Google Scholar
• ErhardtAKolligsFDollingerMTACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multi-center, phase II SOCRATES trialCancer Chemother Pharmacol201474594795425173458
   PubMed Web of Science ®Google Scholar
• ChanKMChouHSWuTJLeeCFYuMCLeeWCCharacterization of hepatocellular carcinoma recurrence after liver transplantation: perioperative prognostic factors, patterns, and outcomeAsian J Surg201134312813422208688
   PubMed Web of Science ®Google Scholar
• DhirMMelinAADouaiherJA review and update of treatment options and controversies in the management of hepatocellular carcinomaAnn Surg201626361112112526813914
   PubMed Web of Science ®Google Scholar
• LeeWCLeeCFChengCHOutcomes of liver resection for hepatocellular carcinoma in liver transplantation eraEur J Surg Oncol20154191144115226163047
   PubMed Web of Science ®Google Scholar